Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Gastrointestinal Neoplasms 1EGFR-Mutated Non-Small-Cell Lung Carcinoma 1Colonic Neoplasms 1Carcinoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 39fludarabine phosphate 37Azacitidine 33fludarabine 25Whole-Body Irradiation 22Busulfan 22Tacrolimus 21Antilymphocyte Serum 21Mycophenolic Acid 19Filgrastim 18Methotrexate 16Melphalan 15venetoclax 13Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Cytarabine 13thymoglobulin 12Cyclosporine 12Thiotepa 9Cord Blood Stem Cell Transplantation 9Alemtuzumab 8Rituximab 7Radiotherapy 7Methylprednisolone 7Decitabine 7Clofarabine 7Lenalidomide 6Stem Cell Transplantation 5Sirolimus 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Myelodysplastic Syndromes × Electrocardiography × Clear all
NCT05918055 2025-12-02

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡